Market Chatter: Eli Lilly, Novo Nordisk Face Pressure in India as Semaglutide Generics Gain Ground

MT Newswires Live04-09

Cheap generic versions of semaglutide in India are beginning to erode the dominance of Eli Lilly's (LLY) tirzepatide-based Mounjaro, Bloomberg reported Thursday.

According to the report, semaglutide's share of India's GLP-1 segment rose to 33% in March from 25% a month earlier after dozens of generic versions entered the market following the local patent expiry of Novo Nordisk's (NVO) blockbuster therapy.

Over the same period, tirzepatide's share dropped to 64% from 71%, the report said, citing Pharmarack data.

Mounjaro sales declined to 1.14 billion Indian rupees ($12.3 million) in March from 1.35 billion rupees in February, Bloomberg reported. Generic semaglutide is now available for as little as $14 per month, it added.

Eli Lilly and Novo Nordisk did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment